Stay updated with breaking news from Supernus Pharms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MIAMI BEACH, Fla. — Administration of Qelbree for up to 1 year showed similar safety, efficacy and tolerability profiles seen in shorter trials with improvement in ADHD symptoms and executive function, according to a study presented here. “The world needs more nonstimulants for ADHD,” Andrew J. Cutler, MD, associate clinical professor in the department of psychiatry, SUNY
In Eurica Califorrniaa v. Vidal, No. 22-1640 (Fed. Cir. Nov. 7, 2022) (non-precedential), the Court of Appeals for the Federal Circuit ("the Federal Circuit") affirmed the district court's grant...
Earlier this month, the Federal Circuit affirmed the grant of summary judgment in favor of the U.S. Patent and Trademark Office by the U.S. District Court for the Eastern District of...
In Sawstop Holding LLC v. Vidal, the Federal Circuit upheld the USPTO’s interpretation of the Patent Term Adjustment (PTA) statute that limits the availability of PTA for time spent...
In Sawstop Holding LLC v. Vidal, the Federal Circuit upheld the USPTO's interpretation of the Patent Term Adjustment (PTA) statute that limits the availability of PTA for time spent appealing an Examiner's rejection.